Six months of COVID vaccines: what 1.7 billion doses have taught scientists.

@article{Ledford2021SixMO,
  title={Six months of COVID vaccines: what 1.7 billion doses have taught scientists.},
  author={Heidi Ledford},
  journal={Nature},
  year={2021},
  volume={594 7862},
  pages={
          164-167
        }
}
Vaccines and the path to recovery
  • Biology
    Nature Reviews Nephrology
  • 2021
Vaccines against SARS-CoV-2 are key to ending the COVID-19 pandemic, but their success depends on global availability and acceptance, as well as measures to protect the most vulnerable.
Global COVID-19 vaccine inequity: The scope, the impact, and the challenges
Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use
TLDR
A massive vaccination drive would be needed to protect people of all ages and would require unprecedented coordination at the national and international levels for generating funds to purchase the required doses of vaccines, fair distribution of doses and managing the mechanics of delivering vaccines throughout the world.
Optimized Post-Vaccination Strategies and Preventative Measures for SARS-CoV-2
TLDR
Specific scenarios exist in which preventative measures taken to prevent SARS-CoV-2 spread, including masking, and testing plus isolation strategies can safely be relaxed, and efficacious testing with quarantine strategies exist in only unvaccinated cohorts in a workplace.
Inclusive access to science in post‐COVID era: Strategic entry points for improved livelihoods
and effective vaccines as quickly as possible. As it turned out, these expectations were met at an exceptional speed. 1 This perhaps represents the greatest triumph of science in the 21st century,
Vaccine Inequity and Hesitancy: A Vicious Cycle Undermining the Fight Against the COVID-19 Pandemic
Abstract The world has come a long way in the fight against the COVID-19 pandemic by averting the initially feared humanitarian crisis and by producing effective vaccines in a record time.
An Intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection
TLDR
An intranasal COVID-19 subunit vaccine, based on a recombinant, six proline stabilized, D614G spike protein (mC-Spike) of SARS-CoV-2 linked via the LPS-binding peptide sequence mCramp to Outer Membrane Vesicles (OMVs) from Neisseria meningitidis is developed.
An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection
TLDR
An intranasal COVID-19 subunit vaccine, based on a recombinant, six-proline-stabilized, D614G spike protein (mC-Spike) of SARS-CoV-2 linked via the LPS-binding peptide sequence mCramp to outer membrane vesicles (OMVs) from Neisseria meningitidis is developed.
Effectiveness of the WHO-Authorized COVID-19 Vaccines: A Rapid Review of Global Reports till 30 June 2021
TLDR
A rapid review revealed a consistently high effectiveness of certain vaccines among the general population in real-world settings, however, scarce data on the major variants of SARS-CoV-2 and the shortness of the study time may limit the conclusions to the mRNA vaccines and ChAdOx1.
Solidarity across borders: A pragmatic need for global COVID‐19 vaccine equity
  • Denise N. Obinna
  • Political Science
    The International journal of health planning and management
  • 2021
TLDR
This work argues that public health policy experts demand a greater need for global solidarity in vaccine access, which is not only important ethically, but it is also a pragmatic response.
...
1
2
3
4
...

References

SHOWING 1-10 OF 12 REFERENCES
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.
TLDR
Analysis of a real-world dataset of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test results after inoculation with the BNT162b2 messenger RNA vaccine found that the viral load was substantially reduced for infections occurring 12-37 d after the first dose of vaccine.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
TLDR
A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B. 1.1.351 variant, and this variant showed greater resistance to the pseudovirus and the live-virus neutralization assays than in samples from placebo recipients.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
TLDR
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
TLDR
The BNT162b2 vaccine in 12-to-15-year-old recipients had a favorable safety profile, produced a greater immune response than in young adults, and was highly effective against Covid-19.
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
TLDR
It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic is provided.
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
TLDR
A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe–critical disease, including hospitalization and death, in an international, randomized, double-blind, placebo-controlled, phase 3 trial.
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
TLDR
Vaccination with either one dose of BNT162b2 or ChAdOx1-S was associated with a significant reduction in symptomatic covid-19 in older adults, and with further protection against severe disease.
...
1
2
...